Both in Biotechnology
Tarsus Pharmaceuticals vs Relay Therapeutics
Over the past year TARS returned +4.1% and RLAY returned +151.3%; their daily moves had a correlation of 0.25.
TARS +4.1% RLAY +151.3%Growth of $1, one year, split-adjusted
| Metric | TARS | RLAY |
|---|---|---|
| Price | $72.64 | $17.44 |
| Market cap | $3.40B | $3.82B |
| Today | −0.93% | +0.93% |
| 1 month | −2.4% | −10.1% |
| 6 months | +11.7% | +34.2% |
| Year to date | −11.3% | +106.1% |
| 1 year | +5.6% | +144.3% |
| Revenue growth (YoY) | +69.4% | −48.3% |
| Gross margin | 93.0% | 100.0% |
| Net margin | −10.7% | −23916.3% |
| P/E (TTM) | — | — |
| Price / sales | 5.6× | 369.3× |
| Net cash | $376.9M | $910.9M |
| Dividend yield | — | — |
| Volatility (60d) | 46.1% | 48.7% |
| Short % of float | 15.3% | 27.9% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).